Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells.

Details

Serval ID
serval:BIB_A09FB31885C9
Type
Article: article from journal or magazin.
Collection
Publications
Title
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells.
Journal
JCI insight
Author(s)
Artibani M., Masuda K., Hu Z., Rauher P.C., Mallett G., Wietek N., Morotti M., Chong K., KaramiNejadRanjbar M., Zois C.E., Dhar S., El-Sahhar S., Campo L., Blagden S.P., Damato S., Pathiraja P.N., Nicum S., Gleeson F., Laios A., Alsaadi A., Santana Gonzalez L., Motohara T., Albukhari A., Lu Z., Bast R.C., Harris A.L., Ejsing C.S., Klemm R.W., Yau C., Sauka-Spengler T., Ahmed A.A.
ISSN
2379-3708 (Electronic)
ISSN-L
2379-3708
Publication state
Published
Issued date
08/06/2021
Peer-reviewed
Oui
Volume
6
Number
11
Pages
e147929
Language
english
Notes
Publication types: Journal Article ; Observational Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Abstract
Similar to tumor-initiating cells (TICs), minimal residual disease (MRD) is capable of reinitiating tumors and causing recurrence. However, the molecular characteristics of solid tumor MRD cells and drivers of their survival have remained elusive. Here we performed dense multiregion transcriptomics analysis of paired biopsies from 17 ovarian cancer patients before and after chemotherapy. We reveal that while MRD cells share important molecular signatures with TICs, they are also characterized by an adipocyte-like gene expression signature and a portion of them had undergone epithelial-mesenchymal transition (EMT). In a cell culture MRD model, MRD-mimic cells showed the same phenotype and were dependent on fatty acid oxidation (FAO) for survival and resistance to cytotoxic agents. These findings identify EMT and FAO as attractive targets to eradicate MRD in ovarian cancer and make a compelling case for the further testing of FAO inhibitors in treating MRD.
Keywords
Adipocytes/metabolism, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carboplatin/administration & dosage, Carcinoma, Ovarian Epithelial/drug therapy, Carcinoma, Ovarian Epithelial/genetics, Carcinoma, Ovarian Epithelial/metabolism, Cell Line, Tumor, Cytoreduction Surgical Procedures, Epithelial-Mesenchymal Transition/genetics, Fatty Acids/metabolism, Female, Humans, Middle Aged, Neoadjuvant Therapy, Neoplasm, Residual/genetics, Neoplasm, Residual/metabolism, Neoplastic Stem Cells/metabolism, Ovarian Neoplasms/drug therapy, Ovarian Neoplasms/genetics, Ovarian Neoplasms/metabolism, Oxidation-Reduction, Paclitaxel/administration & dosage, Transcriptome, Fatty acid oxidation, Obstetrics/gynecology, Oncology
Pubmed
Web of science
Open Access
Yes
Create date
30/07/2021 11:10
Last modification date
22/12/2023 9:30
Usage data